MRTFA and lymphoma: MKL1 knockdown resulted in a more resistant phenotype in both LCL and lymphoma cell lines in Alamar-CDC assays, with an average increase in resistance by 1.7-fold toward ofatumumab (stdev ± 0.69, Figure 3A).